Advertisement

Topics

Vyriad and Sanford Health begin Phase I viro-immunotherapy trial

19:00 EDT 15 Aug 2017 | Net Resources International

US-based biopharmaceutical firm Vyriad has initiated a clinical trial at integrated health system Sanford Health to evaluate a genetically engineered virus for destroying therapy-resistant tumours.

Original Article: Vyriad and Sanford Health begin Phase I viro-immunotherapy trial

NEXT ARTICLE

More From BioPortfolio on "Vyriad and Sanford Health begin Phase I viro-immunotherapy trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...